Multidrug-resistant Acinetobacter baumannii infections: looming threat in the Indian clinical setting

References

• Howard A, O’Donoghue M, Feeney A, et al. Acinetobacter baumannii. Virulence. 2012;3(3):243–250.
   PubMed Web of Science ®Google Scholar
• Said D, Willrich N, Ayobami O, et al. The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014–2018): an analysis of data from the national Antimicrobial Resistance Surveillance system. Antimicrob Resist Infect Control. 2021;10(1):45.
   PubMed Web of Science ®Google Scholar
• Cornejo-Juárez P, Cevallos MA, Castro-Jaimes S, et al. High mortality in an outbreak of multidrug resistant Acinetobacter baumannii infection introduced to an oncological hospital by a patient transferred from a general hospital. PLOS ONE. 2020;15(7):e0234684.
   PubMed Web of Science ®Google Scholar
• Villalón P, Ortega M, Sáez-Nieto JA, et al. Dynamics of a sporadic nosocomial Acinetobacter calcoaceticus – Acinetobacter baumannii complex population. Front Microbiol. 2019;10:593.
   PubMed Web of Science ®Google Scholar
• Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis. 2010;2(3):291–304.
   PubMedGoogle Scholar
• Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem. 2014;6:25–64.
   PubMedGoogle Scholar
• Thirapanmethee K, Srisiri-a-nun T, Houngsaitong J, et al. Prevalence of OXA-Type β-lactamase genes among carbapenem-resistant Acinetobacter baumannii clinical isolates in Thailand. Antibiotics. 2020;9(12):864.
   Web of Science ®Google Scholar
• Piperaki E-T, Tzouvelekis LS, Miriagou V, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2019;25(8):951–957.
   PubMed Web of Science ®Google Scholar
• CDC. Antibiotic-resistant germs: new threats. Centers for Disease Control and Prevention; 2021 [cited 2021 Oct 27]. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html
   Google Scholar
• Mathai AS, Oberoi A, Madhavan S, et al. Acinetobacter infections in a tertiary level intensive care unit in northern India: epidemiology, clinical profiles and outcomes. J Infect Public Health. 2012;5(2):145–152.
   PubMedGoogle Scholar
• Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018;11:1249–1260.
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Mathur P, Kapil A, et al. Molecular characterization & epidemiology of carbapenem-resistant Acinetobacter baumannii collected across India. Indian J Med Res. 2019;149(2):240–246.
   PubMed Web of Science ®Google Scholar
• Rosenthal VD, Bijie H, Maki DG, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control. 2012;40(5):396–407.
   PubMed Web of Science ®Google Scholar
• Hsu L-Y, Apisarnthanarak A, Khan E, et al. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2017;30(1):1–22.
   PubMed Web of Science ®Google Scholar
• Kalal B, Chandran S, Yoganand R, et al. Molecular characterization of carbapenem-resistant Acinetobacter baumannii strains from a tertiary care center in South India. Infectio. 2020;24(1):27.
   Google Scholar
• Rangel K, Chagas TPG, De-Simone SG. Acinetobacter baumannii infections in times of COVID-19 pandemic. Pathogens. 2021;10(8):1006.
   PubMed Web of Science ®Google Scholar
• Sugawara E, Nikaido H. OmpA is the principal nonspecific slow porin of Acinetobacter baumannii. J Bacteriol. 2012;194(15):4089–4096.
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Jacob JJ, Vasudevan K, et al. Colistin resistance in Acinetobacter baumannii is driven by multiple genomic traits: evaluating the role of ISAba1-driven eptA overexpression among Indian isolates. Biorxiv; 2021 [cited 2021 Oct 27] p. 2021.01.07.425695. p. 2021.01.07.425695: https://www.biorxiv.org/content/https://doi.org/10.1101/2021.01.07.425695v1.
   Google Scholar
• Geisinger E, Isberg RR. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 2015;11(2):e1004691.
   PubMed Web of Science ®Google Scholar
• Perez F, Endimiani A, Bonomo RA. Why are we afraid of Acinetobacter baumannii? Expert Rev Anti Infect Ther. 2008;6(3):269–271.
   PubMed Web of Science ®Google Scholar
• Weinberg SE, Villedieu A, Bagdasarian N, et al. Control and management of multidrug resistant Acinetobacter baumannii: a review of the evidence and proposal of novel approaches. Infect Prev Pract. 2020;2(3):100077.
   PubMedGoogle Scholar
• Gandra S, Tseng KK, Arora A, et al. The mortality burden of multidrug-resistant pathogens in India: a retrospective, observational study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;69(4):563–570.
   PubMed Web of Science ®Google Scholar
• Kumar S, Patil PP, Singhal L, et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolates reveals the emergence of blaOXA-23 and blaNDM-1 encoding international clones in India. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2019;75:103986.
   PubMed Web of Science ®Google Scholar
• Tewari R, Chopra D, Wazahat R, et al. Antimicrobial susceptibility patterns of an emerging multidrug resistant nosocomial pathogen: Acinetobacter baumannii. Malaysian J Med Sci MJMS. 2018;25(3):129–134.
   PubMed Web of Science ®Google Scholar
• Kumari M, Batra P, Malhotra R, et al. A 5-year surveillance on antimicrobial resistance of Acinetobacter isolates at a level-I trauma centre of India. J Lab Physicians. 2019;11(1):34–38.
   PubMed Web of Science ®Google Scholar
• Mahantesh S, Manasa S. Prevalence and resistance pattern of Acinetobacter species in PICU and in a tertiary care paediatric hospital in Bangalore. Trop J Pathol Microbiol. 2017;3(2):114–119.
   Google Scholar
• Kaur T, Putatunda C, Oberoi A, et al. Prevalence and drug resistance in Acinetobacter sp. isolated from intensive care units patients in Punjab, India. Asian J Pharm Clin Res. 2018;11(14):88–93.
   Google Scholar
• Banerjee T, Mishra A, Das A, et al. High prevalence and endemicity of multidrug resistant Acinetobacter spp. in intensive care unit of a tertiary care hospital, Varanasi, India. J Pathog. 2018;2018:e9129083.
   PubMed Web of Science ®Google Scholar
• Kaur A, Singh S. Prevalence of Extended Spectrum Betalactamase (ESBL) and Metallobetalactamase (MBL) producing pseudomonas aeruginosa and Acinetobacter baumannii isolated from various clinical samples. J Pathog. 2018;2018:6845985.
   PubMed Web of Science ®Google Scholar
• Baidya S, Sharma S, Mishra SK, et al. Biofilm formation by pathogens causing ventilator-associated pneumonia at intensive care units in a tertiary care hospital: an armor for refuge. BioMed Res Int. 2021;2021:e8817700.
   PubMed Web of Science ®Google Scholar
• John AO, Paul H, Vijayakumar S, et al. Mortality from Acinetobacter infections as compared to other infections among critically ill patients in South India: a prospective cohort study. Indian J Med Microbiol. 2020;38(1):24–31.
   PubMed Web of Science ®Google Scholar
• Mahantesh S, Bhavana J, Basavaraj GV, et al. Ventilator - associated pneumonia in paediatric intensive care unit at the Indira Gandhi Institute of Child Health. IP Indian J Immunol Respir Med. 2021;2(2):36–41.
   Google Scholar
• Gupta M, Lakhina K, Kamath A, et al. Colistin-resistant Acinetobacter baumannii ventilator-associated pneumonia in a tertiary care hospital: an evolving threat. J Hosp Infect. 2016;94(1):72–73.
   PubMed Web of Science ®Google Scholar
• Kaur A, Gill A, Singh S, et al. Prevalence and antibiogram of Acinetobacter spp. isolated from various clinical samples in a tertiary care hospital, Bathinda. Int J Health Sci Res. 2016;6(6):83–89.
   Google Scholar
• Datta P, Rani H, Chauhan R, et al. Health-care-associated infections: risk factors and epidemiology from an intensive care unit in Northern India. Indian J Anaesth. 2014;58(1):30–35.
   PubMedGoogle Scholar
• Khan ID, Basu A, Kiran S, et al. Device-Associated Healthcare-Associated Infections (DA-HAI) and the caveat of multiresistance in a multidisciplinary intensive care unit. Med J Armed Forces India. 2017;73(3):222–231.
   PubMedGoogle Scholar
• Khamari B, Lama M, Pachi Pulusu C, et al. Molecular analyses of biofilm-producing clinical Acinetobacter baumannii isolates from a South Indian tertiary care hospital. Med Princ Pract. 2020;29(6):580–587.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Bhattacharyya I, Rit K, et al. Antibiogram of Acinetobacter spp. isolated from various clinical specimens in a tertiary care hospital, West Bengal, India. Biomed Res. 2013;24(1):43–46.
   Google Scholar
• Sudhaharan S, Vemu L, Kanne P. Prevalence of multidrug resistant Acinetobacter baumannii in clinical samples in a tertiary care hospital. Int J Infect Control. 2015;11(3):1–5.
   Google Scholar
• Rynga D, Shariff M, Deb M. Phenotypic and molecular characterization of clinical isolates of Acinetobacter baumannii isolated from Delhi, India. Ann Clin Microbiol Antimicrob. 2015;14(1):40.
   PubMed Web of Science ®Google Scholar
• Gupta N, Gandham N, Jadhav S, et al. Isolation and identification of Acinetobacter species with special reference to antibiotic resistance. J Nat Sci Biol Med. 2015 Jun;6(1):159–162.
   PubMedGoogle Scholar
• Venkataraman R, Divatia JV, Ramakrishnan N, et al. Multicenter observational study to evaluate epidemiology and resistance patterns of common intensive care unit-infections. Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med. 2018;22(1):20–26.
   PubMed Web of Science ®Google Scholar
• Rajarajacholan UK, Rao R, Sahoo S, et al. Phenotypic and genotypic assays for detecting the prevalence of metallo-lactamases in clinical isolates of Acinetobacter baumannii from a South Indian tertiary care hospital. J Med Microbiol. 2009;58:430–435.
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Kapoor K, Singh V. Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital. Int J Basic Clin Pharmacol. 2020;9(11):1675–1680.
   Google Scholar
• Chandra P, Unnikrishnan MK, Vandana KE, et al. Antimicrobial resistance and the post antibiotic era: better late than never effort. Expert Opin Drug Saf. 2021;20(11):1375–1390.
   PubMed Web of Science ®Google Scholar
• Pawar SK, Karande GS, Shinde RV, et al. Emergence of colistin resistant gram negative bacilli, in a tertiary care rural hospital from Western India. Indian J Microbiol Res. 2021;3(3):308–313.
   Google Scholar
• Pormohammad A, Mehdinejadiani K, Gholizadeh P, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Microb Pathog. 2020;139:103887.
   PubMed Web of Science ®Google Scholar
• Fonseca EL, Scheidegger E, Freitas FS, et al. Carbapenem-resistant Acinetobacter baumannii from Brazil: role of car O alleles expression and blaOXA-23 gene. BMC Microbiol. 2013;13:245.
   PubMed Web of Science ®Google Scholar
• Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol. 2013;4:48.
   PubMed Web of Science ®Google Scholar
• Amudhan SM, Sekar U, Arunagiri K, et al. OXA beta-lactamase-mediated carbapenem resistance in Acinetobacter baumannii. Indian J Med Microbiol. 2011;29(3):269–274.
   PubMed Web of Science ®Google Scholar
• Pillonetto M, Arend L, Vespero EC, et al. First report of NDM-1-producing Acinetobacter baumannii sequence type 25 in Brazil. Antimicrob Agents Chemother. 2014;58(12):7592–7594.
   PubMed Web of Science ®Google Scholar
• Matsui M, Suzuki M, Suzuki M, et al. Distribution and molecular characterization of Acinetobacter baumannii International Clone II Lineage in Japan. Antimicrob Agents Chemother. 2018;62(2):e02190–17.
   PubMed Web of Science ®Google Scholar
• Rao RS, Karthika RU, Singh S, et al. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of. Indian J Med Microbiol. 2008;26(4):5.
   PubMed Web of Science ®Google Scholar
• Singla P, Sikka R, Deeep A, et al. Co-production of ESBL and AmpC β-Lactamases in Clinical Isolates of A. baumannii and A. lwoffii in a Tertiary Care Hospital From Northern India. J Clin Diagn Res JCDR. 2014;8(4):DC16–9.
   PubMedGoogle Scholar
• Kansal R, Pandey A, Asthana AK. β-lactamase producing Acinetobacter species in hospitalized patients. Indian J Pathol Microbiol. 2009;52(3):456.
   PubMed Web of Science ®Google Scholar
• Pragasam A, Vijayakumar S, Bakthavatchalam Y, et al. Molecular characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected across India. Indian J Med Microbiol. 2016;34(4):433–441.
   PubMed Web of Science ®Google Scholar
• Gurung J, Khyriem AB, Banik A, et al. Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit. Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med. 2013;17(4):214–218.
   PubMed Web of Science ®Google Scholar
• Badave GK, Kulkarni D. Biofilm producing multidrug resistant Acinetobacter baumannii: an emerging challenge. J Clin Diagn Res JCDR. 2015;9(1):DC08–DC10.
   PubMed Web of Science ®Google Scholar
• Saranathan R, Vasanth V, Vasanth T, et al. Emergence of carbapenem non-susceptible multidrug resistant Acinetobacter baumannii strains of clonal complexes 103B and 92B harboring OXA-type carbapenemases and metallo-β-lactamases in Southern India. Microbiol Immunol. 2015;59(5):277–284.
   PubMed Web of Science ®Google Scholar
• Kumar S, Sen P, Gaind R, et al. Prospective surveillance of device-associated health care-associated infection in an intensive care unit of a tertiary care hospital in New Delhi, India. Am J Infect Control. 2018;46(2):202–206.
   PubMed Web of Science ®Google Scholar
• Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;71(9):2459–2468.
   PubMed Web of Science ®Google Scholar
• Ghanshani R, Gupta R, Gupta BS, et al. Epidemiological study of prevalence, determinants, and outcomes of infections in medical ICU at a tertiary care hospital in India. Lung India Off Organ Indian Chest Soc. 2015;32(5):441–448.
   PubMed Web of Science ®Google Scholar
• Tiwari P, Rohit M. Assessment of costs associated with hospital-acquired infections in a private tertiary care hospital in India. Value Health Reg Issues. 2013;2(1):87–91.
   PubMedGoogle Scholar
• Nelson RE, Schweizer ML, Perencevich EN, et al. Costs and mortality associated with multidrug-resistant healthcare-associated Acinetobacter infections. Infect Control Hosp Epidemiol. 2016;37(10):1212–1218.
   PubMed Web of Science ®Google Scholar
• Asim P, Naik NA, Muralidhar V, et al. Clinical and economic outcomes of Acinetobacter vis a vis non-Acinetobacter infections in an Indian teaching hospital. Perspect Clin Res. 2016;7(1):28–31.
   PubMedGoogle Scholar
• Teerawattanapong N, Kengkla K, Dilokthornsakul P, et al. Prevention and control of multidrug-resistant gram-negative bacteria in adult intensive care units: a systematic review and network meta-analysis. Clin Infect Dis. 2017;64(suppl_2):S51–60.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(s1):1–55.
   PubMed Web of Science ®Google Scholar
• Sharma S, Kaur N, Malhotra S, et al. Control of an outbreak of Acinetobacter baumannii in burn unit in a tertiary care hospital of North India. Adv Public Health. 2014;2014:e896289.
   Google Scholar